Cargando…
临床疑诊肺癌纵隔淋巴结转移EBUS-TBNA阴性患者的处理
BACKGROUND AND OBJECTIVE: Endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) is well known as an important technique for diagnosis and staging of lung cancer. But a standard protocol to deal with patients who have a negative pathology result still needs to be defined. Herei...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500495/ https://www.ncbi.nlm.nih.gov/pubmed/31014440 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.04 |
_version_ | 1783415956478885888 |
---|---|
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: Endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) is well known as an important technique for diagnosis and staging of lung cancer. But a standard protocol to deal with patients who have a negative pathology result still needs to be defined. Herein, we describe the subsequent procedures of these patients in a single center. METHODS: A total of 1, 412 patients with clinical suspected lung cancer and mediastinal metastasis who underwent EBUS-TBNA were collected between September 2010 and December 2016. Among them, 51 patients with nonspecific pathology result were included and retrospectively analyzed. RESULTS: The 51 patients were stratified into five groups by clinical characterize and follow-up procedures: (1) Diagnosed by other bronchoscopy procedures group (9 cases). Abnormalities of tracheobronchial tree were found during visual examination in the majority of patients (8 cases). Biopsy, endobronchial brushing, bronchoalveolar lavage, and transbronchial lung biopsy (TBLB) were used to get a specific diagnosis. (2) EBUS-TBNA re-biopsy group (11 cases). Patients in this group had normal mucosal appearance and airway lumen. Re-biopsy were performed on patients in this group. (3) Surgery group (6 cases). Patients underwent surgery after negative result of EBUS-TBNA. Five of them were confirmed with non-nodal metastasis after surgery. (4) Underwent other pathology diagnosis group (15 cases). patients in this group had other metastasis sites besides midiastinal lymph node. Computed tomography (CT)-guided fine-needle aspiration and lymph node biopsy were performed. (5) Follow-up group (10 cases). None invasive procedure was used in this group. The median follow up time was 38 months. One patient was diagnosed lymphoma during the follow up. CONCLUSION: Diagnostic procedures should be chosen based on the clinical character in EBUS-TBNA negative patients with suspected lung cancer. Long time follow-up is very important in patients whose diagnosis is apparently unknown. |
format | Online Article Text |
id | pubmed-6500495 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-65004952019-05-21 临床疑诊肺癌纵隔淋巴结转移EBUS-TBNA阴性患者的处理 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: Endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) is well known as an important technique for diagnosis and staging of lung cancer. But a standard protocol to deal with patients who have a negative pathology result still needs to be defined. Herein, we describe the subsequent procedures of these patients in a single center. METHODS: A total of 1, 412 patients with clinical suspected lung cancer and mediastinal metastasis who underwent EBUS-TBNA were collected between September 2010 and December 2016. Among them, 51 patients with nonspecific pathology result were included and retrospectively analyzed. RESULTS: The 51 patients were stratified into five groups by clinical characterize and follow-up procedures: (1) Diagnosed by other bronchoscopy procedures group (9 cases). Abnormalities of tracheobronchial tree were found during visual examination in the majority of patients (8 cases). Biopsy, endobronchial brushing, bronchoalveolar lavage, and transbronchial lung biopsy (TBLB) were used to get a specific diagnosis. (2) EBUS-TBNA re-biopsy group (11 cases). Patients in this group had normal mucosal appearance and airway lumen. Re-biopsy were performed on patients in this group. (3) Surgery group (6 cases). Patients underwent surgery after negative result of EBUS-TBNA. Five of them were confirmed with non-nodal metastasis after surgery. (4) Underwent other pathology diagnosis group (15 cases). patients in this group had other metastasis sites besides midiastinal lymph node. Computed tomography (CT)-guided fine-needle aspiration and lymph node biopsy were performed. (5) Follow-up group (10 cases). None invasive procedure was used in this group. The median follow up time was 38 months. One patient was diagnosed lymphoma during the follow up. CONCLUSION: Diagnostic procedures should be chosen based on the clinical character in EBUS-TBNA negative patients with suspected lung cancer. Long time follow-up is very important in patients whose diagnosis is apparently unknown. 中国肺癌杂志编辑部 2019-04-20 /pmc/articles/PMC6500495/ /pubmed/31014440 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.04 Text en 版权所有©《中国肺癌杂志》编辑部2019 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
spellingShingle | 临床研究 临床疑诊肺癌纵隔淋巴结转移EBUS-TBNA阴性患者的处理 |
title | 临床疑诊肺癌纵隔淋巴结转移EBUS-TBNA阴性患者的处理 |
title_full | 临床疑诊肺癌纵隔淋巴结转移EBUS-TBNA阴性患者的处理 |
title_fullStr | 临床疑诊肺癌纵隔淋巴结转移EBUS-TBNA阴性患者的处理 |
title_full_unstemmed | 临床疑诊肺癌纵隔淋巴结转移EBUS-TBNA阴性患者的处理 |
title_short | 临床疑诊肺癌纵隔淋巴结转移EBUS-TBNA阴性患者的处理 |
title_sort | 临床疑诊肺癌纵隔淋巴结转移ebus-tbna阴性患者的处理 |
topic | 临床研究 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500495/ https://www.ncbi.nlm.nih.gov/pubmed/31014440 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.04 |
work_keys_str_mv | AT línchuángyízhěnfèiáizònggélínbājiézhuǎnyíebustbnayīnxìnghuànzhědechùlǐ AT línchuángyízhěnfèiáizònggélínbājiézhuǎnyíebustbnayīnxìnghuànzhědechùlǐ AT línchuángyízhěnfèiáizònggélínbājiézhuǎnyíebustbnayīnxìnghuànzhědechùlǐ AT línchuángyízhěnfèiáizònggélínbājiézhuǎnyíebustbnayīnxìnghuànzhědechùlǐ AT línchuángyízhěnfèiáizònggélínbājiézhuǎnyíebustbnayīnxìnghuànzhědechùlǐ AT línchuángyízhěnfèiáizònggélínbājiézhuǎnyíebustbnayīnxìnghuànzhědechùlǐ AT línchuángyízhěnfèiáizònggélínbājiézhuǎnyíebustbnayīnxìnghuànzhědechùlǐ AT línchuángyízhěnfèiáizònggélínbājiézhuǎnyíebustbnayīnxìnghuànzhědechùlǐ AT línchuángyízhěnfèiáizònggélínbājiézhuǎnyíebustbnayīnxìnghuànzhědechùlǐ |